<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580641</url>
  </required_header>
  <id_info>
    <org_study_id>RNI 2018 MOISSET (Q-MIGAL)</org_study_id>
    <nct_id>NCT04580641</nct_id>
  </id_info>
  <brief_title>Validation of a Questionnaire for Allodynia in Migraine.</brief_title>
  <acronym>Q-MIGAL</acronym>
  <official_title>Allodynia and Sensorial Hypersensitivity in Patients With Migraine: Validation of a Specific Questionnaire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Migraine is very frequent (15% of the general population). During attacks, many subjects with&#xD;
      migraine have allodynia (pain induced by normally non-painful stimuli), photophobia&#xD;
      (hypersensitivity to light), phonophobia (hypersensitivity to sound) or osmophobia&#xD;
      (hypersensitivity to odours). The goal of the present study is to validate a new&#xD;
      questionnaire made of 4 parts evaluating the presence of these 4 types of hypersensitivity,&#xD;
      both during or between migraine attacks. It will allow to look for associations of these 4&#xD;
      symptoms and association of hypersensitivity with patients' or migraine's characteristics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of migraine is around 15% worldwide (GBD 2016, Lancet Neurol 2018). During&#xD;
      attacks, and even between attacks, especially when migraine frequency is high, many subjects&#xD;
      with migraine present with photophobia, phonophobia, osmophobia or allodynia. These symptoms&#xD;
      are though to correspond to central sensitization and can be found in animal models of&#xD;
      migraine (Boyer et al., Pain 2017; Dallel et al., Cephalalgia 2018).&#xD;
&#xD;
      These 4 symptoms have been studied separately in previous studies but to date, there is no&#xD;
      overall questionnaire evaluating these 4 sub-types of hypersensitivity. The investigators&#xD;
      have constituted a questionnaire based on previous validated questionnaires that have been&#xD;
      translated into French (Lipton et al., 2008 for cutaneous allodynia; Choi et al., 2009 for&#xD;
      photophobia), a previous questionnaire validated in French (Khalfa et al, 2002 for&#xD;
      phonophobia) and created a few questions for each of the 4 symptoms, including osmophobia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive factors of allodynia/hypersensitivity in subjects with migraine</measure>
    <time_frame>baseline</time_frame>
    <description>Correlations between scores on specific questionnaires evaluating allodynia/hypersensitivity (cutaneous allodynia with the questionnaire by Lipton et al., 2008, osmophobia with a home-made questionnaire rated from 0 to 4, photophobia with the questionnaire by Choi et al., 2009, phonophobia with the questionnaire by Khalfa et al., 2002), patients characteristics (age, sex, Body mass index, habits, score on the Hospital Anxiety and Depression scale) and migraine characteristics (presence of aura or not, migraine duration in years, migraine frequency in attacks per month, pain intensity during migraine attacks rated from 0 to 4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of cutaneous allodynia in subjects with migraine</measure>
    <time_frame>baseline</time_frame>
    <description>Correlations between score on the 12-item Allodynia Symptom Checklist (Lipton et al., 2008) (score from 0 to 24 with higher values indicating higher level of allodynia), patients characteristics (age in years, sex, body mass index in kg/m², consumption of alcohol and tobacco, score on the Hospital Anxiety and Depression scale) and migraine characteristics (presence of aura or not, migraine duration in years, migraine frequency in attacks per month, pain intensity during migraine attacks rated from 0 to 4) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of photophobia in subjects with migraine</measure>
    <time_frame>baseline</time_frame>
    <description>Correlations between scores on two specific questionnaires evaluating photophobia (Choi et al., 2009; binary score for presence or absence of photophobia and home-made questionnaire with score from 0 to 4 with higher values indicating higher level of phonophobia), patients characteristics (age in years, sex, body mass index in kg/m², consumption of alcohol and tobacco, score on the Hospital Anxiety and Depression scale) and migraine characteristics (presence of aura or not, migraine duration in years, migraine frequency in attacks per month, pain intensity during migraine attacks rated from 0 to 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of phonophobia in subjects with migraine</measure>
    <time_frame>baseline</time_frame>
    <description>Correlations between scores on a questionnaire evaluating phonophobia (Khalfa et al. 2002, score from 0 to 42 with higher values indicating higher level of phonophobia), patients characteristics (age in years, sex, body mass index in kg/m², consumption of alcohol and tobacco, score on the Hospital Anxiety and Depression scale) and migraine characteristics, (presence of aura or not, migraine duration in years, migraine frequency in attacks per month, pain intensity during migraine attacks rated from 0 to 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors of osmophobia in subjects with migraine</measure>
    <time_frame>baseline</time_frame>
    <description>Correlations between scores on a specific home-made questionnaire evaluating osmophobia (score from 0 to 4 with higher values indicating higher level of osmophobia), patients characteristics (age in years, sex, body mass index in kg/m², consumption of alcohol and tobacco, score on the Hospital Anxiety and Depression scale) and migraine characteristics (presence of aura or not, migraine duration in years, migraine frequency in attacks per month, pain intensity during migraine attacks rated from 0 to 4).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Subjects with migraine</arm_group_label>
    <description>No medical intervention. All included subjects will filled in the questionnaire concerning migraine characteristics and associated symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>A self-administered questionnaire will be completed by each study subject</description>
    <arm_group_label>Subjects with migraine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects fulfilling 2018 international headache society criteria for migraine&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects fulfilling 2018 international headache society criteria for migraine.&#xD;
&#xD;
          -  Age &gt; 17 years.&#xD;
&#xD;
          -  Written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of neurological comorbidities that could lead to sensorial or sensitive&#xD;
             abnormalities&#xD;
&#xD;
          -  Presence of dermatological comorbidities that could lead to sensorial or sensitive&#xD;
             abnormalities&#xD;
&#xD;
          -  Presence of ENT comorbidities that could lead to sensorial or sensitive abnormalities&#xD;
&#xD;
          -  Significant cognitive dysfunction precluding proper completion of the&#xD;
             self-administered questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Moisset, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Laclautre, PharmD</last_name>
    <phone>04 73 754 963</phone>
    <phone_ext>33</phone_ext>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH d'Annecy, Centre d'Etude et de Traitement de la Douleur</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Pierric GIRAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet de Neurologie</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Michel LAUXEROIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand, Centre d'Etude et de Traitement de la Douleur</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand, Service de Neurologie</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier MOISSET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélissa ZUEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Emile Roux Le Puy en Velay, Service de Neurologie</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <zip>43000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Jérémy DASSA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille, Service de Neurologie</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon, Hôpital Pierre Wertheimer, Service de neurologie fonctionelle et épileptologie</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Geneviève DEMARQUAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Marseille, CHU La Timone, Centre d'Evaluation et Traitement de la Douleur</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Anne DONNET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier, Service de Neurologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Anne DUCROS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Service de Neurologie</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Solène DE GAALON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice, Département Evaluation et Traitement de la Douleur</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Michel LANTERI-MINET, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris, CHU Lariboisière, Service de Neurologie</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline ROOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérome MAWET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen, Service de Neurologie</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Evelyne MASSARDIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Vichy, Service de Neurologie</name>
      <address>
        <city>Vichy</city>
        <zip>03200</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise Laclautre, PharmD</last_name>
      <phone>0473754963</phone>
      <phone_ext>33</phone_ext>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Mitra NAJJAR-RAVAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Choi JY, Oh K, Kim BJ, Chung CS, Koh SB, Park KW. Usefulness of a photophobia questionnaire in patients with migraine. Cephalalgia. 2009 Sep;29(9):953-9. doi: 10.1111/j.1468-2982.2008.01822.x. Epub 2009 Feb 27.</citation>
    <PMID>19298545</PMID>
  </reference>
  <reference>
    <citation>Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF; American Migraine Prevalence Prevention Advisory Group. Cutaneous allodynia in the migraine population. Ann Neurol. 2008 Feb;63(2):148-58.</citation>
    <PMID>18059010</PMID>
  </reference>
  <reference>
    <citation>Khalfa S, Dubal S, Veuillet E, Perez-Diaz F, Jouvent R, Collet L. Psychometric normalization of a hyperacusis questionnaire. ORL J Otorhinolaryngol Relat Spec. 2002 Nov-Dec;64(6):436-42.</citation>
    <PMID>12499770</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>allodynia</keyword>
  <keyword>photophobia</keyword>
  <keyword>phonophobia</keyword>
  <keyword>osmophobia</keyword>
  <keyword>central sensitization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

